WA-TANIUM
6.1.2022 21:41:12 CET | Business Wire | Press release
Industry experts are naming Log4j one of the most severe internet and computer vulnerabilities they have encountered. The United States Cyber Security and Infrastructure Security Agency (CISA) Director stated that the Log4j vulnerability: “…is one of the most serious I’ve seen in my entire career, if not the most serious.”
Log4j is the perfect storm of severity, pervasiveness, and ease of exploitability. It is an open-source code library widely used inside commercial and open-source software applications. The recently discovered vulnerability allows hackers to take complete control of affected endpoints with a single line of code. As a result, finding and fixing every single instance of Log4j and applications that rely on it is critical for corporate networks.
The key to finding all instances of Log4j is the ability to look inside every file in a corporate network and Tanium is the only solution that, in minutes, can look inside every file, and find every instance of Log4j, at scale today.
Tanium is supporting organizations globally in the eradication of Log4j vulnerabilities. The Tanium Platform uniquely enables organizations to manage their exposure by:
- Looking inside nested archive folders and files for vulnerabilities
- Finding references to Log4j even if they were renamed (maliciously or by design)
- Automating software upgrades and patches at scale to all vulnerable systems
- Watching, alerting, and remediating any new instance of the vulnerability that is inadvertently introduced post-cleanup
Ring Power Corp. was able to scan every file and folder and find every single instance of Log4j with their entire environment in only minutes. “Tanium Reveal has been critical to us in responding to Log4j. Nobody else was able to search for references to the impacted library in common file formats and detect instances of exploitation. With Tanium, we accomplished in 30 minutes what would have taken months.” - Kevin Bush, VP of IT at Ring Power Corp.
Salisbury University stated “We saw first-hand the strength of Tanium during the Log4j vulnerability crisis. Tanium made us aware of many endpoints that were vulnerable to Log4j through user-installed tools and applications that we weren’t aware of.” – Steven Blankenship, Director of IT
To set up a Tanium evaluation of your environment for the Log4j vulnerability, please contact us at https://www.tanium.com/log4j/ .
About Tanium
Tanium is the platform that the most demanding and complex organizations trust to gain visibility and control across all endpoints in on-premises, cloud and hybrid environments. Tanium addresses today’s increasing IT challenges with high fidelity endpoint data — giving IT operations, security and risk teams confidence to quickly manage, secure and protect their networks at scale. Nearly half of the Fortune 100, top retailers and financial institutions, and multiple branches of the U.S. Armed Forces trust Tanium to help see and control every endpoint, everywhere. That’s the power of certainty. Tanium has been named to the Forbes Cloud 100 list of “Top 100 Private Companies in Cloud Computing” for six consecutive years and ranks on FORTUNE’s list of the “Best Large Workplaces in Technology 2021.” Visit www.tanium.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005859/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom